HAEMONETICS CORP (HAE) FY2025 10-K Annual Report
HAEMONETICS CORP (HAE) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on May 21, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
HAEMONETICS CORP FY2025 10-K Analysis
Business Overview
- • Core business: Medical devices and technologies for plasma collection, blood centers, and hospitals
- • Emphasis on Plasma and Hospital segments as primary growth drivers; Blood Center focused on targeted plasma and platelet opportunities
- • Strategic divestiture of Whole Blood product line to align portfolio with long-term objectives
- • Top 10 customers accounted for 42% of net revenues in fiscal 2025; largest Plasma customer contract extended non-exclusively through Dec 2025
- • New market and regional alignment initiative approved in fiscal 2026 aimed at cost reduction and operational performance improvement
Management Discussion & Analysis
- • Revenue $1.361B, up 4.0% YoY; Hospital segment up 23.7% ($564M vs $456M), Plasma down 6.0% ($535M vs $570M), Blood Center down 7.8% ($261M vs $283M)
- • Operating margin 16.3% vs 12.6%; gross margin 55.0% vs 52.8%; net income margin 12.3% vs 9.0%
- • Best performing segment Hospital with 23.7% growth to $564M; worst Blood Center with 7.8% decline to $261M
- • Share repurchase: $300M completed with new $500M authorization; Capex and acquisition spending includes $187.7M for Attune Medical, $254.5M for OpSens; $65.8M cash received from divestiture of Whole Blood product line
- • Forward outlook: $20M restructuring charge expected through FY2027 with annualized $30M savings; focus on growth in Plasma and Hospital; risks from foreign exchange and market dynamics noted
Risk Factors
- • Regulatory risk from SEC Rule 10b5-1 affecting timing and execution of $500M share repurchase program through April 2028
- • Share repurchase program could increase stock price volatility and reduce market liquidity for common stock
- • Share repurchases constrained by compliance with loan covenants impacting cash flow flexibility
- • Potential stock price decline below repurchase cost risking shareholder value erosion
- • No specific geopolitical, competitive, or operational risks disclosed in this section
HAEMONETICS CORP FY2025 Key Financial MetricsXBRL
Revenue
$1.4B
▲ +4.0% YoY
Net Income
$168M
▲ +42.6% YoY
Gross Margin
55.0%
▲ +221bp YoY
Operating Margin
16.3%
▲ +370bp YoY
Net Margin
12.3%
▲ +334bp YoY
ROE
20.4%
▲ +818bp YoY
Total Assets
$2.5B
▲ +11.6% YoY
EPS (Diluted)
$3.31
▲ +44.5% YoY
Operating Cash Flow
$182M
▼ -0.0% YoY
Source: XBRL data from HAEMONETICS CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on HAEMONETICS CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.